Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. - Wikidata - awgldk - TriplyDB

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

http://www.wikidata.org/entity/Q35362684

about

Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis Viral hepatitis and hepatocellular carcinoma Tyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adults Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law Diagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-Analysis Review article: the management of autoimmune hepatitis beyond consensus guidelines Non-invasive diagnosis of focal liver lesions: an individualized approach Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china Hepatocellular carcinoma: a review Model-guided therapy for hepatocellular carcinoma: a role for information technology in predictive, preventive and personalized medicine Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012.Screening and surveillance for hepatocellular carcinoma: perspective of a new era?Management strategies for hepatocellular carcinoma: old certainties and new realities.In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft.Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients.Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost.In vivo application of short-lag spatial coherence imaging in human liver.Current role of ultrasound for the management of hepatocellular carcinoma Diagnosis of hepatocellular carcinoma.Review article: percutaneous treatment of hepatocellular carcinoma.The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis.Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community.Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial.Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis.Progression of liver cirrhosis to HCC: an application of hidden Markov model.Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma.Cost-effectiveness of liver cancer screening in adults at high risk for liver cancer in the republic of Korea.Recent developments in the first detection of hepatocellular carcinoma Laser ablation for small hepatocellular carcinoma.Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis RETRACTED: Gene expression profiling analysis of hepatocellular carcinoma Role of ultrasonography in the staging of gastrointestinal neoplasms.PKM2 regulates Gli1 expression in hepatocellular carcinoma.Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.

P2860

Q21144594-A06DF8BD-5E52-4B46-8882-6DCBE57E7F3C Q21245597-5597714B-E463-4EE6-B55F-566DE9E0CAE7 Q24187730-38C6F7E9-6273-40B4-9BC3-1CF15CE693A6 Q24635267-C2B2B661-FF18-45FA-A057-902EA506D9DF Q26740317-CCB3B631-3E00-487F-AAC6-625C7E903F7D Q26797581-D76CAD9B-1C8C-419F-8935-9FDF429D2AE2 Q26863560-1E26E7A6-31FA-4948-930D-8F54B8A89469 Q26864272-21F094E4-D283-47AE-8F71-9D638DC2855F Q26999766-9FBAB731-2477-465F-85DA-BD0B104A73C4 Q27003291-532D1B71-12E0-4E51-8803-84218D779A72 Q28069290-264727CF-0402-4FE2-8E4E-95728E3CB442 Q28087569-1287F366-57C4-465E-94E2-612598807576 Q30151390-DEF3B42D-A1B0-4370-B1E3-DA9E7C410D9E Q30244651-37B7B187-36F9-42B3-A563-EF69CF5415A5 Q30252143-B1CE462D-A69E-4A8D-AFC8-44AEE5FE6930 Q30372076-2D31964B-4BDE-48A4-B8B7-BBA4CCDFF3C4 Q30375738-676BC271-77DF-463A-8276-4C7609938211 Q30422199-14DFB8DB-8C36-4E78-BA24-AB4E1A66F948 Q30429663-6F33ADC9-1290-41D2-BFB0-3759B5E7C962 Q30442495-ABB22E95-5E14-4199-BA74-BF2497CA0F5D Q30488974-98BA4D00-2132-420B-8387-4F9C9C5D98BA Q30490554-EB450B07-6A3E-498C-AF8B-E90A6254596A Q30942931-AA5D75DF-7210-4930-82FB-2D3CEFD8A95B Q33272872-8C404800-B865-497A-BBA2-3B703E8ECA3D Q33405296-A62EDA13-F0E1-42C3-998A-2B7EA5E7E5BF Q33576986-EED4F251-DA78-4F93-8733-CA110AA8DC8F Q33642229-6F22793F-5015-4778-A66C-3E929DC738D1 Q33643368-E88A5FDD-14B4-4124-A13A-00D9A10EEA78 Q33685277-239590E3-9062-474E-8D6D-FD6134F21091 Q33686038-4F4392CA-3A5B-463D-A3F8-BDD47B1E685C Q33860546-4D28D365-5233-42A7-A9D1-37F45C1638D6 Q33866389-F4F1E5AA-0162-4702-8CB2-56692226A9C1 Q34043444-6ACDABF7-32AE-4CC8-9182-B3A61B348998 Q34055894-DF1C09F6-7E6A-4DD5-8DC5-CA1CA719574B Q34108430-E8B12BFF-A465-4526-AFD5-9EF8D650320F Q34189361-EB702BA4-C896-4FEA-808E-F45E61F41DD3 Q34253636-CDD9951C-B637-4951-BFF0-3F088D2E33C7 Q34277255-7BC26049-B8B4-4067-838B-0E2B8F720518 Q34293185-9C549AAF-B518-4303-97BA-55664618A12E Q34409128-37306EF4-9378-4B2E-84A1-DF4F0A0F0391

P2860

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

http://www.wikidata.org/entity/Q35362684

description

2001 nî lūn-bûn

@nan

2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Surveillance programme of cirr ...... a cost effectiveness analysis.

@ast

Surveillance programme of cirr ...... a cost effectiveness analysis.

@en

type

label

Surveillance programme of cirr ...... a cost effectiveness analysis.

@ast

Surveillance programme of cirr ...... a cost effectiveness analysis.

@en

prefLabel

Surveillance programme of cirr ...... a cost effectiveness analysis.

@ast

Surveillance programme of cirr ...... a cost effectiveness analysis.

@en

P1433

Q35362684-44ED22A0-9C8D-4363-93E2-6F2171F8FE84

P1476

Q35362684-55013BBA-C928-4179-8DEE-49D22FB91395

P2093

Q35362684-08F40911-48FA-4A13-80BE-119F0196878F

Q35362684-2A6F1C14-8190-451F-B89B-F76D59EBB88F

Q35362684-4798E863-7E5F-4B1B-9506-2D949E68DB58

Q35362684-6AF5F1E0-4998-4321-A4BF-25DF4966E592

Q35362684-6E70165C-ED65-47C3-A333-F98548F65A3C

Q35362684-76A3BB1C-A133-4EB2-A31E-641F6671394E

Q35362684-A1FFF316-0860-411F-883C-ACA698B873A6

Q35362684-B658DF8D-DBA4-4C3F-9906-CBA4C69DE85E

P2860

Q35362684-118C84E1-3E05-486B-9510-A1BAC879175C

Q35362684-11CBB384-19D7-4644-A2EE-F1B2AF35D2C5

Q35362684-19A2D1E6-D6F3-4C7C-9FBE-0E3970544A40

Q35362684-1A3CC0F4-7F70-4E5A-8BE8-6020BF333C2E

Q35362684-231CD8AA-9F6E-47D6-9594-578DBE516D52

Q35362684-2F287BC3-E081-4848-9E42-1DF70DF0A122

Q35362684-366DF12A-F10C-4BC3-82E2-7A61F617C83D

Q35362684-407064A0-1D4B-43F0-A70B-5CE0F0F9CA38

Q35362684-4E0B8E70-FF36-4AB6-AC21-9AEC92C73974

Q35362684-555947EE-8038-4AAA-9931-1B2BB97373CD

P304

Q35362684-4EAE0895-3B37-4048-8353-E7FBB37FCA5A

P31

Q35362684-C771D7C0-A4E5-4A41-AFE5-E8C642FACE74

P356

Q35362684-0F2E402C-7E56-4A32-9C8A-AEA31BA04532

P407

Q35362684-1F60991A-B07F-439D-BB13-90A30DCF69EC

P433

Q35362684-B5B43245-0189-4F0D-9717-F617567B3D9F

P478

Q35362684-1F6F9B7F-404F-4FB8-A47B-816A00221A6F

P50

Q35362684-56AA619E-52B5-4D8B-9AA1-B091EA5A7F3B

Q35362684-BA0F736B-623F-47FA-A8D4-241A2A11D196

P577

Q35362684-7B2F2F0D-3B07-46B2-A67C-0CAD42D07F5B

P5875

Q35362684-7F5FB26B-BDEB-4CA9-A131-03769D602C4E

P698

Q35362684-EDA2135B-2942-46E7-91A4-720BDD459437

P921

Q35362684-706C60FF-CAA5-4084-8265-2053DD2EDADC

P932

Q35362684-D70EDBC5-0358-4773-9FA2-1829FB5D5FD4

P356

P1433

P1476

Surveillance programme of cirr ...... a cost effectiveness analysis

@en

P2093

A Casali

http://www.w3.org/2001/XMLSchema#string

G Zironi

http://www.w3.org/2001/XMLSchema#string

L Bolondi

http://www.w3.org/2001/XMLSchema#string

M Sherman

http://www.w3.org/2001/XMLSchema#string

M Zanetti

http://www.w3.org/2001/XMLSchema#string

S Gaiani

http://www.w3.org/2001/XMLSchema#string

S Siringo

http://www.w3.org/2001/XMLSchema#string

S Sofia

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Gains in life expectancy from medical interventions--standardizing data on outcomes.

Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Transection of the oesophagus for bleeding oesophageal varices.

Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis.

Costs of breast cancer and the cost-effectiveness of breast cancer screening.

A clinician's guide to cost-effectiveness analysis.

The distinction between cost and charges.

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.

Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients.

P304

251-259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.48.2.251

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Laura Gramantieri

Fabio Piscaglia

P577

2001-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277456118

http://www.w3.org/2001/XMLSchema#string

P698

11156649

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

P932

1728189

http://www.w3.org/2001/XMLSchema#string